Teal cell membrane with one receptor-like form and a folded peptide ribbon.

Our evidence assessments are specific to an outcome, population, and formulation.

Read our grading method

Semaglutide

Weight-loss trials and what happens after treatment is discontinued.

Weight management
Written by

Recorded source check: 3 October 2026

Review and updates

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and the active ingredient in Wegovy, which is available in oral and subcutaneous formulations.[1] The clinical weight-management research summarized here examines defined groups of adults and specified treatment regimens, rather than every product sold under the ingredient name.[2] Its interpretation depends on the formulation, indication, accompanying care, and length of follow-up, including what happens when treatment stops.[2] This guide brings those benefit findings together with the product’s labeled safety information, interaction questions, and quality considerations so that a trial result remains connected to the circumstances in which it was obtained.

Benefits

In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[2] Its results should not be generalized to every dose, route, or patient group.[2]

Safety

The Wegovy label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[1] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[1] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[1] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[1]

Contraindications

The Wegovy label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and semaglutide/excipient hypersensitivity.[1] Separate pregnancy guidance for weight management directs discontinuation when pregnancy is recognized and at least two months before planned pregnancy.[1] Breastfeeding is not recommended with tablets; injection labeling calls for individualized assessment because milk-transfer and infant-effect data are missing.[1] Severe gastroparesis is a separate not-recommended precaution.[1]

Interactions

Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral medicines, including those requiring close monitoring.[1] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance. The relevant product information and clinical setting should guide interpretation of each specific concern.

Forms & dosing

Wegovy tablets and subcutaneous injections have separate escalation, maintenance, administration and switching instructions.[1] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use. The same ingredient name does not establish equivalence between different preparations or indications.

Results & stopping

Wegovy is labeled for long-term weight maintenance; its Medication Guide directs clinician discussion after multiple missed weekly injections.[1] Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[3]

Product quality

FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved drugs and says their chemical and pharmacologic equivalence is not established.[4] The agency has also received reports of dosing errors with compounded semaglutide injections, including cases requiring hospitalization.[4] A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[5] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[5]

Status

Wegovy has approved weight-management indications; eligibility and other indications differ between oral and injectable formulations.[1] Compounded semaglutide is not FDA-approved and does not undergo the agency's premarket review for safety, effectiveness and quality.[6] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources
Human researchLarge double-blind randomized placebo-controlled trial.[2]

In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2]

Main limitation: Average trial response does not predict an individual's result.[2]

Human researchObservational extension of a randomized trial.[3]

Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3]

Main limitation: Selected follow-up subset; drug and lifestyle intervention both stopped.[3]

Product-testing researchSmall observational test-purchase and laboratory study.[5]

A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5]

Main limitation: Documents failures; does not estimate market-wide prevalence.[5]

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

PDF recordArtificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis
PDF recordBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
PDF recordComparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study
PDF recordComparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non‑randomized study
PDF recordDose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared with placebo and open‑label semaglutide in people with type 2 diabetes: a randomised clinical trial
PDF recordEffect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
PDF recordEffect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
PDF recordEffects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
PDF recordEfficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
PDF recordEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE
PDF recordEfficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus
PDF recordEfficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
PDF recordEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
PDF recordEfficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
PDF recordEfficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
PDF recordEfficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double‑blind, Phase IIIa, randomised trial
PDF recordEfficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double‑blind, Phase IIIa, randomised trial
PDF recordExploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH
PDF recordHigh-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial
PDF recordImpact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach
PDF recordImproved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial
PDF recordIndirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
PDF recordInsulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial
PDF recordLong-acting PYY336 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
PDF recordLong-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
PDF recordLong-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
PDF recordOnce‑weekly IcoSema versus once‑weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
PDF recordOnce-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase IIb single-centred clinical trial
PDF recordOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
PDF recordOral semaglutide for Alcohol Use Disorder: A randomized clinical trial
PDF recordPharmacokinetics, Safety and Tolerability of Once- Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
PDF recordSafety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
PDF recordSafety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
PDF recordSemaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
PDF recordSemaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study
PDF recordSemaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study
PDF recordSemaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
PDF recordSemaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
PDF recordOnce-Weekly Semaglutide in Adults with Overweight or Obesity
PDF recordSemaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
PDF recordWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
PDF recordevoke and evoke+: design of two largescale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
PDF recordSemaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
PDF recordTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
PDF recordLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
PDF recordLong-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
PDF recordEffects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
PDF recordRandomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
PDF recordEffects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
PDF recordSemaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
PDF recordThe effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
PDF recordGastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

FAQs

How much weight loss did semaglutide produce in a major clinical trial?
Quick answer:

In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[2] Its results should not be generalized to every dose, route, or patient group.[2]

What happens to weight after stopping semaglutide?
Quick answer:

Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[3]

Does a 99% purity claim mean a peptide is safe to inject?
Quick answer:

A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[5] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[5]

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Semaglutide.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

10 sources
  1. WEGOVY U.S. Prescribing Information, revised June 2026 (2026)Regulatory labelingSave study
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)Primary researchReview status · PendingSave study
  3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)Primary researchReview status · PendingSave study
  4. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Accessed 2026-10-03)Regulatory assessmentSave study
  5. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (2024)Primary researchReview status · PendingSave study
  6. FDA: Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory assessmentSave study
  7. Discussionr/SemaglutideHas anyone switched from Tirzepatide to Semaglutide? Less effective? More effective?
  8. Discussionr/SemaglutideTrying to decide between tirzepatide vs semaglutide anyone have real experience with both
  9. Discussionr/SemaglutideHow to not regain it all back?
  10. Discussionr/GLP1AustraliaWeight rebound after stopping

Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions